These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 17375339)

  • 1. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
    Navari RM; Einhorn LH; Loehrer PJ; Passik SD; Vinson J; McClean J; Chowhan N; Hanna NH; Johnson CS
    Support Care Cancer; 2007 Nov; 15(11):1285. PubMed ID: 17375339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
    Navari RM; Einhorn LH; Passik SD; Loehrer PJ; Johnson C; Mayer ML; McClean J; Vinson J; Pletcher W
    Support Care Cancer; 2005 Jul; 13(7):529-34. PubMed ID: 15700131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Navari RM; Nagy CK; Gray SE
    Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
    Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
    Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
    Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
    Einhorn LH; Brames MJ; Dreicer R; Nichols CR; Cullen MT; Bubalo J
    Support Care Cancer; 2007 Nov; 15(11):1293-1300. PubMed ID: 17436025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.
    Celio L; Denaro A; Canova S; Gevorgyan A; Bajetta E
    Tumori; 2008; 94(4):447-52. PubMed ID: 18822676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.
    Celio L; Frustaci S; Denaro A; Buonadonna A; Ardizzoia A; Piazza E; Fabi A; Capobianco AM; Isa L; Cavanna L; Bertolini A; Bichisao E; Bajetta E;
    Support Care Cancer; 2011 Aug; 19(8):1217-25. PubMed ID: 20574663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
    Boccia R; Grunberg S; Franco-Gonzales E; Rubenstein E; Voisin D
    Support Care Cancer; 2013 May; 21(5):1453-60. PubMed ID: 23354552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
    Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
    Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results.
    Lorusso V; Spedicato A; Petrucelli L; Saracino V; Giampaglia M; Perrone T
    Support Care Cancer; 2009 Dec; 17(12):1469-73. PubMed ID: 19294429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
    Navari RM; Gray SE; Kerr AC
    J Support Oncol; 2011; 9(5):188-95. PubMed ID: 22024310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
    Celio L; Agustoni F; Testa I; Dotti K; de Braud F
    Tumori; 2012; 98(3):279-86. PubMed ID: 22825501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.
    Celio L; Denaro A; Agustoni F; Bajetta E
    J Support Oncol; 2012; 10(2):65-71. PubMed ID: 22005217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.